36.74
0.06 (0.16%)
| Penutupan Terdahulu | 36.68 |
| Buka | 36.79 |
| Jumlah Dagangan | 219,954 |
| Purata Dagangan (3B) | 365,217 |
| Modal Pasaran | 2,028,757,120 |
| Harga / Pendapatan (P/E TTM) | 34.34 |
| Harga / Pendapatan (P/E Ke hadapan) | 20.16 |
| Harga / Jualan (P/S) | 3.15 |
| Harga / Buku (P/B) | 2.02 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | 9.16% |
| Margin Operasi (TTM) | 16.12% |
| EPS Cair (TTM) | 1.07 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 14.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.79% |
| Nisbah Semasa (MRQ) | 2.19 |
| Aliran Tunai Operasi (OCF TTM) | 172.50 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 162.93 M |
| Pulangan Atas Aset (ROA TTM) | 2.89% |
| Pulangan Atas Ekuiti (ROE TTM) | 6.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Supernus Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.88 |
|
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.07% |
| % Dimiliki oleh Institusi | 113.20% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| KHATTAR JACK A. | - | 37.18 | -25,233 | -938,163 |
| RUBIN JONATHAN | - | 37.18 | -1,102 | -40,972 |
| Jumlah Keseluruhan Kuantiti Bersih | -26,335 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -979,135 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 37.18 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KHATTAR JACK A. | Pegawai | 27 Dec 2024 | Dibuang (-) | 25,233 | 37.18 | 938,163 |
| KHATTAR JACK A. | Pegawai | 27 Dec 2024 | Pelaksanaan pilihan | 52,640 | - | - |
| RUBIN JONATHAN | Pegawai | 27 Dec 2024 | Dibuang (-) | 1,102 | 37.18 | 40,972 |
| RUBIN JONATHAN | Pegawai | 27 Dec 2024 | Pelaksanaan pilihan | 2,625 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 26 Nov 2024 | Pengumuman | Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference |
| 13 Nov 2024 | Pengumuman | Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference |
| 04 Nov 2024 | Pengumuman | Supernus Announces Third Quarter 2024 Financial Results |
| 31 Oct 2024 | Pengumuman | Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 |
| 21 Oct 2024 | Pengumuman | Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results |
| 17 Oct 2024 | Pengumuman | Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder |
| 10 Oct 2024 | Pengumuman | Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |